Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in more than 75 countries, we are proud to have reached millions of people with our products.
Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one prior therapy
Citric Acid Monohydrate, Lysine Hydrochloride (stabilizer, 25.55 mg), Polysorbate 80, Trehalose Dihydrate (stabilizer, 105.0 mg), Sodium Hydroxide[IV Solution Stabilizer] 1 vial (10 mL) contains Citric Acid Monohydrate (52.5 mg), Lysine Hydrochloride (2283.8 mg), Polysorbate 80 (10 mg), Sodium Hydroxide (q.s.), Water For Injection (q.s.)
1. MRD-positive B-cell Precursor ALL
THIS DRUG is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.
2. Relapsed or Refractory B cell Precursor ALL
THIS DRUG is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.